New combo drug aims to stop chemo-induced vomiting in advanced breast cancer
NCT ID NCT07132749
First seen Jan 11, 2026 · Last updated May 22, 2026 · Updated 12 times
Summary
This study looks at whether a drug called NEPA (netupitant/palonosetron) can prevent nausea and vomiting in people with advanced HER2-positive or HER2-low breast cancer who are being treated with T-DXd. About 100 adults will take NEPA and be monitored for up to 504 hours after each dose. The goal is to see if they can avoid vomiting and needing rescue medication, especially during the long-delayed phase.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATIENTS WITH HER2-POSITIVE ADVANCED BREAST CANCER TREATED WITH T-DXD are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Samsung Medical Center
Seoul, Gangnam-gu, 06355, South Korea
Conditions
Explore the condition pages connected to this study.